Skip header and navigation

Refine By

2 records – page 1 of 1.

A Comparison of Sex Differences in Psychotropic Medication Use in Older People with Alzheimer's Disease in the US and Finland.

https://arctichealth.org/en/permalink/ahliterature285249
Source
Drugs Aging. 2017 Jan;34(1):55-65
Publication Type
Article
Date
Jan-2017
Author
Daniela C Moga
Heidi Taipale
Anna-Maija Tolppanen
Antti Tanskanen
Jari Tiihonen
Sirpa Hartikainen
Qishan Wu
Gregory A Jicha
Danijela Gnjidic
Source
Drugs Aging. 2017 Jan;34(1):55-65
Date
Jan-2017
Language
English
Publication Type
Article
Keywords
Adult
Aged
Aged, 80 and over
Alzheimer Disease - drug therapy - psychology
Anti-Anxiety Agents - administration & dosage - therapeutic use
Antidepressive Agents - administration & dosage - therapeutic use
Antipsychotic Agents - administration & dosage - therapeutic use
Drug Utilization - statistics & numerical data
Female
Finland - epidemiology
Humans
Hypnotics and Sedatives - administration & dosage - therapeutic use
Logistic Models
Male
Middle Aged
Odds Ratio
Prevalence
Psychotropic Drugs - administration & dosage - therapeutic use
Sex Characteristics
United States - epidemiology
Abstract
Given the high prevalence of psychotropic medication use in people with dementia and the potential for different prescribing practices in men and women, our study aimed to investigate sex differences in psychotropic medication use in older adults with Alzheimer's disease (AD) living in the US and Finland.
We used data collected between 2005 and 2011 as part of the National Alzheimer's Coordinating Center (NACC) in the US, and Medication use and Alzheimer's disease (MEDALZ) cohorts in Finland. We evaluated psychotropic medication use (antidepressant, antipsychotic, anxiolytic, sedative, or hypnotic) in participants aged 65 years or older. We employed multivariable logistic regression adjusted for demographics, co-morbidities, and other medications to estimate the magnitude of the association (adjusted odds ratio [aOR] with 95% confidence intervals [CIs]) according to sex.
We included 1099 NACC participants (502 [45.68%] men, 597 [54.32%] women), and 67,049 participants from the MEDALZ cohort (22,961 [34.24%] men, 44,088 [65.75%] women). Women were more likely than men to use psychotropic medications: US, 46.2% vs. 33.1%, p 
Notes
Cites: Alzheimer Dis Assoc Disord. 2009 Apr-Jun;23(2):91-10119474567
Cites: Clin Pharmacol Ther. 2012 Mar;91(3):521-822297385
Cites: J Epidemiol Community Health. 2006 Jan;60(1):7-1216361448
Cites: J Am Geriatr Soc. 2013 Jan;61(1):55-6123301833
Cites: Am J Geriatr Psychiatry. 2015 Dec;23(12):1259-6926525997
Cites: Int Psychogeriatr. 2009 Jun;21(3):469-7519243654
Cites: Int Clin Psychopharmacol. 2015 Jul;30(4):202-826011780
Cites: Neurology. 1994 Dec;44(12):2308-147991117
Cites: J Clin Psychiatry. 2012 Dec;73(12):1548-5423290328
Cites: JAMA. 2005 Oct 19;294(15):1934-4316234500
Cites: Cochrane Database Syst Rev. 2006 Jan 25;(1):CD00347616437455
Cites: PLoS One. 2014 Jan 13;9(1):e8322424454696
Cites: Int J Geriatr Psychiatry. 2009 Oct;24(10):1079-8619280678
Cites: Neurology. 1993 Nov;43(11):2412-48232972
Cites: J Neuropsychiatry Clin Neurosci. 2000 Spring;12(2):233-911001602
Cites: Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4):210-617132964
Cites: Int Clin Psychopharmacol. 2014 Jul;29(4):216-2324608822
Cites: J Am Geriatr Soc. 2014 Jun;62(6):1046-5524823451
Cites: Eur Neuropsychopharmacol. 2014 Nov;24(11):1729-3725453487
Cites: J Psychiatr Res. 1975 Nov;12(3):189-981202204
Cites: Pharmacoepidemiol Drug Saf. 2007 May;16(5):560-7017286304
Cites: Ann Med. 2012 Aug;44(5):458-6721495785
Cites: Maturitas. 2016 Nov;93:114-12027506133
Cites: J Clin Psychopharmacol. 2014 Aug;34(4):435-4024875073
Cites: Arch Gen Psychiatry. 2011 Feb;68(2):190-721300946
Cites: Lancet. 2011 Jul 30;378(9789):403-1121764118
Cites: JAMA. 2016 Nov 8;316(18):1865-186627802499
Cites: Am J Geriatr Pharmacother. 2007 Jun;5(2):147-6117719517
Cites: Clin Epidemiol. 2013 Aug 07;5:277-8523950660
Cites: J Alzheimers Dis. 2014;41(4):1223-824787914
Cites: Ann Pharmacother. 2009 Jul;43(7):1233-819584395
Cites: Scand J Public Health. 2016 Mar;44(2):150-826553247
Cites: BMC Geriatr. 2015 Nov 14;15:14826572734
Cites: BMC Med Inform Decis Mak. 2015 Mar 25;15:2125890003
Cites: J Epidemiol Community Health. 2006 Feb;60(2):95-10116415256
Cites: Alzheimer Dis Assoc Disord. 2004 Oct-Dec;18(4):270-715592144
Cites: Alzheimer Dis Assoc Disord. 2007 Jul-Sep;21(3):249-5817804958
Cites: Int J Geriatr Psychiatry. 2002 Aug;17(8):733-812211123
Cites: J Am Geriatr Soc. 2013 May;61(5):723-3323590231
Cites: Int J Geriatr Psychiatry. 2006 Sep;21(9):824-3016955439
Cites: Age Ageing. 2016 Jul;45(4):535-4227151390
Cites: Neurology. 1984 Jul;34(7):939-446610841
Cites: JAMA. 2016 Nov 8;316(18):1863-186427802482
PubMed ID
27896799 View in PubMed
Less detail

Risk of Hip Fracture in Benzodiazepine Users With and Without Alzheimer Disease.

https://arctichealth.org/en/permalink/ahliterature287836
Source
J Am Med Dir Assoc. 2017 Jan;18(1):87.e15-87.e21
Publication Type
Article
Date
Jan-2017
Author
Laura Saarelainen
Anna-Maija Tolppanen
Marjaana Koponen
Antti Tanskanen
Reijo Sund
Jari Tiihonen
Sirpa Hartikainen
Heidi Taipale
Source
J Am Med Dir Assoc. 2017 Jan;18(1):87.e15-87.e21
Date
Jan-2017
Language
English
Publication Type
Article
Keywords
Aged
Aged, 80 and over
Alzheimer Disease - drug therapy - psychology
Benzodiazepines - adverse effects
Female
Finland
Hip Fractures - etiology
Humans
Male
Odds Ratio
Registries
Retrospective Studies
Risk Assessment - methods
Abstract
To investigate the association between benzodiazepine and related drug (BZDR) use and hip fracture as well as postfracture mortality and duration of hospital stay in community-dwellers with and without Alzheimer disease (AD).
Retrospective cohort study.
The register-based Medication Use and Alzheimer's disease (MEDALZ) study, including all community-dwelling persons diagnosed with AD in Finland during 2005-2011 (n = 70,718) and their matched comparison persons without AD.
Persons without BZDR use during the year preceding the AD diagnosis or the corresponding matching date as well as persons without history of hip fracture were included in this study.
We investigated the risk of hip fracture associated with BZDR use compared with nonuse separately in persons with and without AD. Further, we investigated the association between BZDR use during hip fracture and 1-year mortality as well as longer than a 4-month hospital stay after hip fracture. Associations were reported as hazard ratios and odds ratios with 95% confidence intervals (CI).
BZDR use was associated with an increased risk of hip fracture in persons with and without AD (adjusted hazard ratio 1.4 [95% CI 1.2-1.7] and 1.6 [95% CI 1.3-1.9], respectively). BZDR use during hip fracture was associated with longer than 4-month postfracture hospital stay in persons with AD [adjusted odds ratio 1.9 (95% CI 1.3-2.8)] but not in comparison persons. One-year mortality was not associated with BZDR use during hip fracture.
Higher threshold in prescribing BZDRs for neuropsychiatric symptoms might decrease the hip fracture rate and affect the length of hospital stay in persons with AD.
PubMed ID
27847263 View in PubMed
Less detail